Abstract
Merkel cell carcinoma (MCC) is an aggressive cutaneous malignancy with neuroendocrine origin. The rarity of the tumor and variable clinical presentation make the diagnosis especially challenging. The tumor grows rapidly and lymph node metastasis occurs early in the disease course. The etiology is related to prior UV exposure, immunosuppression, and polyomavirus infection. The 2008 discovery of an infectious cause for the majority of Merkel cell carcinoma cases sparked more research into the pathogenesis of the tumor and possible therapeutic options. Although there has been recent improvement, there is a lack of uniform consensus or well-established guidelines on the management of MCC. These difficulties in identifying and treating the disease, as well as the overall poor prognosis, highlight the importance of further research into the area, and the requirement for physicians to stay up to date with the most recent research findings.
Keywords: Merkel, polyomavirus, organ transplant, skin cancer, immunosuppression.
Current Cancer Therapy Reviews
Title:Merkel Cell Carcinoma: Epidemiology, Clinical Presentations, Histology, Polyomavirus Involvement, and Management
Volume: 12 Issue: 1
Author(s): Bahar Bahrani, Hannah Liu, Elizabeth M Marchionne and Amor Khachemoune
Affiliation:
Keywords: Merkel, polyomavirus, organ transplant, skin cancer, immunosuppression.
Abstract: Merkel cell carcinoma (MCC) is an aggressive cutaneous malignancy with neuroendocrine origin. The rarity of the tumor and variable clinical presentation make the diagnosis especially challenging. The tumor grows rapidly and lymph node metastasis occurs early in the disease course. The etiology is related to prior UV exposure, immunosuppression, and polyomavirus infection. The 2008 discovery of an infectious cause for the majority of Merkel cell carcinoma cases sparked more research into the pathogenesis of the tumor and possible therapeutic options. Although there has been recent improvement, there is a lack of uniform consensus or well-established guidelines on the management of MCC. These difficulties in identifying and treating the disease, as well as the overall poor prognosis, highlight the importance of further research into the area, and the requirement for physicians to stay up to date with the most recent research findings.
Export Options
About this article
Cite this article as:
Bahrani Bahar, Liu Hannah, Marchionne M Elizabeth and Khachemoune Amor, Merkel Cell Carcinoma: Epidemiology, Clinical Presentations, Histology, Polyomavirus Involvement, and Management, Current Cancer Therapy Reviews 2016; 12 (1) . https://dx.doi.org/10.2174/1573394712666160714151154
DOI https://dx.doi.org/10.2174/1573394712666160714151154 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Cancer Drug Design Using Natural and Synthetic Pharmacophores
Current Organic Chemistry Inhibitors of Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Therapy Stratifications and Novel Approach in Pursuit of Aids Related Kaposi’s Sarcoma Management- A paradigm for Non Invasiveness
Current Drug Delivery Expression of Defensins in Gingiva and Their Role in Periodontal Health and Disease
Current Pharmaceutical Design Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets Impact of Renin-Angiotensin System in Hepatocellular Carcinoma
Current Cancer Drug Targets The p53-Estrogen Receptor Loop in Cancer
Current Molecular Medicine Recent Advances in Anti-Survivin Treatments for Cancer
Current Medicinal Chemistry Oxidative Stress, Redox Signaling and Cancer Chemoresistance: Putting Together the Pieces of the Puzzle
Current Medicinal Chemistry A Review of Light Sources and Enhanced Targeting for Photodynamic Therapy
Current Medicinal Chemistry In Vitro Intestinal Co-Culture Cell Model to Evaluate Intestinal Absorption of Edelfosine Lipid Nanoparticles
Current Topics in Medicinal Chemistry Statins and Cancer
Anti-Cancer Agents in Medicinal Chemistry Autophagy and Cell Death in Caenorhabditis elegans
Current Pharmaceutical Design Indole Derivatives as Anticancer Agents for Breast Cancer Therapy: A Review
Anti-Cancer Agents in Medicinal Chemistry The Pharmacological Pathways of GnRH Mediating the Inhibition of Mammary Tumours: Implications in Humans and Domestic Animals
Current Medicinal Chemistry The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Molecular Pathways Associated with Aggressiveness of Papillary Thyroid Cancer
Current Genomics Copper Compounds in Anticancer Strategies
Current Medicinal Chemistry Peroxisome Proliferator Activated Receptor α Ligands as Anticancer Drugs Targeting Mitochondrial Metabolism
Current Pharmaceutical Biotechnology Antihistamines: Past Answers and Present Questions
Current Drug Safety